Philip Morris: Outpacing The Market, With More Room To Run
Philip Morris International shows robust growth in smoke-free products. Find out why PM stock remains a solid buy with ...
ADC Therapeutics targets $600M–$1B in peak ZYNLONTA revenue amid expansion into DLBCL market
Q4 2024 Management View CEO Ameet Mallik highlighted that 2024 was focused on execution, achieving key milestones, advancing ZYNLONTA, and strengthening the balance sheet. The company completed ...
Opinion | Why the FDA is right about Zyn
The FDA recently authorized marketing of 20 Zyn nicotine pouches with flavors like Wintergreen and Chill. Despite what TikTok ...
Investor's Business Daily on MSN4d
This Tobacco Giant's Business Shift Moves It Near The Top Of The S&P 500
Philip Morris is soaring on the Zyn nicotine pouch craze and is now in a valid base, trading just below a buy point.